Computed Tomography Screening and Small Cell Lung Cancer Stage Shift and Survival

Importance Lung cancer screening with low-dose computed tomography (LDCT) has been shown to identify lung cancers at earlier stages and to significantly reduce lung cancer mortality in prior randomized clinical trials. However, the benefit of LDCT screening for small cell lung cancer (SCLC), an aggressive subtype of lung cancer, is unclear. Objective To investigate the characteristics and outcomes of SCLC diagnosed after a lung cancer screening examination using a large database of Medicare beneficiaries. Design, Setting, and Participants In this retrospective cohort study, Medicare data linked to the Surveillance Epidemiology End Results Program’s cancer registry data were analyzed. Patients in the US aged 65 to 78 years who were diagnosed with SCLC from 2015 to 2021 were identified for analysis, with follow-up data through 2022. Patients who underwent 1 or more LDCT lung cancer screening examinations during the 12 months preceding their SCLC diagnosis were included in the screened group. All other patients were included in the unscreened group. Data were analyzed from January to August 2026. Exposure One or more LDCT lung cancer screenings during the 12 months preceding SCLC diagnosis. Main Outcomes and Measures The primary outcomes were stage at SCLC diagnosis and overall survival after SCLC diagnosis in the screened and unscreened groups. Results A total of 17 099 patients (median [IQR] age, 72.0 [69.0-75.0] years; 8999 [52.6%] female) met study inclusion criteria, of which 949 (5.5%) were included in the screened group and 16 150 (94.5%) were included in the unscreened group. When compared with patients in the unscreened group, patients in the screened group were significantly less likely to be diagnosed with distant disease (419 of 949 [44.2%] vs 11 376 of 16 150 [70.4%]; P < .001). Patients in the screened group also had significantly better overall survival when compared with patients in the unscreened group (3-year overall survival, 28.0% [95% CI, 24.9%-31.2%] vs 10.8% [95% CI, 10.3%-11.3%]; P < .001). Both findings were consistent in propensity score–matched analysis. Conclusions and Relevance Results of this cohort study of Medicare beneficiaries diagnosed with SCLC suggest that receipt of lung cancer screening was associated with a shift toward earlier-stage SCLC at diagnosis and improved overall survival.

Authors

Institutions

Publication Details

Journal
JAMA Oncology
Published
2026-11-19
DOI
https://doi.org/10.1001/jamaoncol.2026.4667
Primary Topic
Lung Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Computed Tomography Screening and Small Cell Lung Cancer Stage Shift and Survival

Chi‐Fu Jeffrey Yang, Lecia Van Dam Sequist, Priyanka Senthil, George C. Linderman et al.
JAMA Oncology
Lung Cancer Diagnosis and Treatment
article

Computed Tomography Screening and Small Cell Lung Cancer Stage Shift and Survival

Chi‐Fu Jeffrey Yang, Lecia Van Dam Sequist, Priyanka Senthil, George C. Linderman, Allison E.B. Chang, Deepti H. Srinivasan, Alexandra L. Potter, Soneesh Kothagundla, Aniruth Ananthanarayanan, Timothy Hwang, Donna Tong
article en

Abstract

Importance Lung cancer screening with low-dose computed tomography (LDCT) has been shown to identify lung cancers at earlier stages and to significantly reduce lung cancer mortality in prior randomized clinical trials. However, the benefit of LDCT screening for small cell lung cancer (SCLC), an aggressive subtype of lung cancer, is unclear. Objective To investigate the characteristics and outcomes of SCLC diagnosed after a lung cancer screening examination using a large database of Medicare beneficiaries. Design, Setting, and Participants In this retrospective cohort study, Medicare data linked to the Surveillance Epidemiology End Results Program’s cancer registry data were analyzed. Patients in the US aged 65 to 78 years who were diagnosed with SCLC from 2015 to 2021 were identified for analysis, with follow-up data through 2022. Patients who underwent 1 or more LDCT lung cancer screening examinations during the 12 months preceding their SCLC diagnosis were included in the screened group. All other patients were included in the unscreened group. Data were analyzed from January to August 2026. Exposure One or more LDCT lung cancer screenings during the 12 months preceding SCLC diagnosis. Main Outcomes and Measures The primary outcomes were stage at SCLC diagnosis and overall survival after SCLC diagnosis in the screened and unscreened groups. Results A total of 17 099 patients (median [IQR] age, 72.0 [69.0-75.0] years; 8999 [52.6%] female) met study inclusion criteria, of which 949 (5.5%) were included in the screened group and 16 150 (94.5%) were included in the unscreened group. When compared with patients in the unscreened group, patients in the screened group were significantly less likely to be diagnosed with distant disease (419 of 949 [44.2%] vs 11 376 of 16 150 [70.4%]; P < .001). Patients in the screened group also had significantly better overall survival when compared with patients in the unscreened group (3-year overall survival, 28.0% [95% CI, 24.9%-31.2%] vs 10.8% [95% CI, 10.3%-11.3%]; P < .001). Both findings were consistent in propensity score–matched analysis. Conclusions and Relevance Results of this cohort study of Medicare beneficiaries diagnosed with SCLC suggest that receipt of lung cancer screening was associated with a shift toward earlier-stage SCLC at diagnosis and improved overall survival.

JAMA Oncology
Massachusetts General Hospital (US), Mass General Brigham (US)
Lung Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon